GSK plc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.67. The key difference: GSK plc pays a 3.57% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and GSK plc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| GSK | KOLD | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $49.39 |
52-Week Low | $38.22 | $13.58 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
KOLD trades at $28.54, down 0.35% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF tracks natural gas price movements inversely, with recent news highlighting volatility in natural gas markets driven by weather patterns and LNG demand. Support levels cluster around $28 with resistance at $29-$30.
As a leveraged ETF, KOLD carries significant volatility risks and is designed for short-term trading rather than long-term investment. The natural gas market faces headwinds from production levels and storage data, while geopolitical developments and weather patterns create trading opportunities for tactical investors.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →